Analyst picks & changes
| Company || Bank || Analyst || Coverage || Opinion || Wk chg || 6/7 cls |
| Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) || Leerink || Joseph Schwartz || Upgrade || Outperform (from market perform) || 7% || $15.97 |
| Schwartz also raised his target to $21 from $16 on the belief that the Street "underestimates the magnitude of potential EPS accretion" from Auxilium's acquisition of urology company Actient Pharmaceuticals LLC, which Auxilium disclosed in its 1Q13 earnings. Schwartz said Actient is a "very profitable cash-generating business," and with about 100 Actient sales representatives already focused on urology surgeons treating Peyronie's disease, he is optimistic for a successful launch of Auxilium's Xiaflex/Xiapex collagenase clostridium histolyticum. The injectable form of collagenase to treat Peyronie's has a Sept.
Read the full 1273 word article